David McIntosh: Moving Beyond Doubts and Ensuring the Safety of Plasma Donation
David McIntosh, Founder and Chair of United Plasma Action, shared on LinkedIn about a recent article by Peter Jaworski, adding:
”The safety of plasma donation.
This interesting publication in Professor Jaworski‘s substack is full of relevant data – and hugely encouraging for anyone who might have been harbouring doubts about the safety of plasma donation by pheresis.
The footnote that I believe it may be helpful to add is as follows:
- The safety of all donations, both patient safety and donor safety – depends on good practice; thoroughly good practice all down the line, from donor health screening to patient treatment.
Every step of the way, risk avoidance and mitigation must be top priorities.
- The safety of those processes is not affected by the colour of the donor’s socks. It is not affected by the brand of tea provided post-donation, nor the type of biscuit served.
Nor is it affected by administrative details such as donor motivation, recognition or reward, or whether or not the collection organisation works for- or not-for-profit.
All collectors are subject to the same rigorous Safety and Quality obligations.
- Where there are safety risks – as in almost any human activity there are bound to be – these will not be mitigated by dispersing incense, sounding bells or burning candles.
Nor will they be mitigated by preaching ‘altruistic’ donation.
(By all means feel free to sing your favourite hymn while donating, but please be aware that there are much more scientific precautions already being taken on your behalf, as a matter of routine – precautions that have nothing to do with attitudes to donor motivation or reward….. )
- This most recent study was clearly motivated by some lingering notion that somehow the sector of the international plasma community that produces and delivers some 90% of the World’s current supplies for patients is – or might be – defective in some way; might pose a serious risk either to patients or donors, or both.
This notion is patently utterly absurd, but is constantly propagated by not-for-profit sector interests, for reasons that are not always clear, but almost certainly have more to do with not-for-profit organisational funding and survival than they have to do with any genuine concern about safety of any kind.
- Meanwhile – amidst all the earnest talk about irrelevant details – millions of patients in the World who desperately need plasma-derived medicines, simply aren’t getting any.
Could the commercial and the not-for-profit folks please get together and decide to tackle the real problems – not argue about illusory ones?”
Stay updated with Hemostasis Today.
-
Jun 24, 2026, 13:50Tijjani Balas: Why Early Detection of DVT Matters
-
Jun 24, 2026, 13:43Brandon Michael Henry: Interpreting Complement Activation After AAV Gene Therapy
-
Jun 24, 2026, 13:37Heba Youssef: Heparin-Induced Thrombocytopenia – The Prothrombotic Emergency You Cannot MissÂ
-
Jun 24, 2026, 13:32Jecko Thachil: Understanding the Clinical Spectrum of Vitamin B12
-
Jun 24, 2026, 13:32Namrata Singh: Beyond Low Platelets – Understanding What Triggers ITP
-
Jun 24, 2026, 09:29Advancing Women’s Health Through Collaboration with Jean Hailes for Women’s Health – Stroke Foundation
-
Jun 24, 2026, 09:18The Lasting Immunological Footprint of VITT – JTH
-
Jun 24, 2026, 09:09Umberto Pensato: Dedicated Funding Pathways for Stroke Research in Italy
-
Jun 24, 2026, 09:00Danny Gaskin: BBTS 2026 and the Evolving Role of Transfusion in Maternity Care